S14 Ep42: Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/37/d9/f9/37d9f9c6-c820-66f3-7a4b-459aefa0484a/mza_9223874801391949533.jpg/600x600bb.jpg

OncLive® On Air

500 episodes

3 days ago

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Health & Fitness

Science

RSS

All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Health & Fitness

Science

https://audioboom.com/i/43179019/s=1400x1400/el=1/rt=fill.png

S14 Ep42: Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

OncLive® On Air

4 minutes

2 weeks ago

S14 Ep42: Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

Dr Mian discussed why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic